Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced the launch of a new formula for Taltz (ixekizumab) in China, following its approval in the country in November of the previous year. The new formula of the IL-17A monoclonal antibody (mAb) is free from citrate salts, maintaining a concentration of 80 milligrams per milliliter and featuring the same active pharmaceutical ingredients (APIs) as the original formula.
Initially approved in China in August 2019, Taltz was indicated for the treatment of moderate-to-severe plaque psoriasis in patients eligible for systemic therapy or phototherapy. It later expanded its indications to include active ankylosing spondylitis (AS) that has shown a poor response to conventional therapy, with market approval received in 2022. The new Taltz formula offers a significant reduction in injection site pain for some patients, with an 86% reduction in pain levels as measured by the Visual Analogue Scale (VAS) compared to the original formula.- Flcube.com
